Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 11/20 | 0.35 |
| ▸ | CA2 | P00918 | 11/20 | 0.35 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710814 | 0.91 | ACACB (0.38) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL13400241 | 0.91 | CA1 (0.40) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL1710803 | 0.87 | EPHX1 (0.39) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL1710454 | 0.85 | EPHX1 (0.39) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL1710846 | 0.84 | EPHX1 (0.38) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL1710605 | 0.84 | CA1 (0.38) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL3388472 | 0.84 | CA1 (0.41) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL3388591 | 0.83 | CA1 (0.39) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL13400275 | 0.82 | ACACB (0.41) | EPHX1ACACBCA1CA2CA12 | |
| SCHEMBL3385740 | 0.82 | ACACB (0.38) | EPHX1ACACBCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | EPHX1 3213/4885ACACB 2089/4885CA1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.